Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Innoviva, Inc. stock logo
INVA
Innoviva
$20.77
-1.0%		$22.15
$16.52
▼
$25.15
$1.55B0.35759,119 shs799,097 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.80
-2.8%		$3.90
$2.23
▼
$6.51
$1.21B1.124.53 million shs5.26 million shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$3.02
+5.6%		$5.08
$2.74
▼
$8.59
$270.12M1.691.73 million shs7.82 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$31.13
-1.0%		$24.55
$13.50
▼
$44.60
$1.98B-1.03806,917 shs429,281 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Innoviva, Inc. stock logo
INVA
Innoviva
0.00%-2.19%-6.01%-9.26%+12.56%
MannKind Corporation stock logo
MNKD
MannKind
0.00%-5.33%-13.50%+37.68%+4.27%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.00%-49.02%-52.25%-40.42%-26.85%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
0.00%+3.46%+15.46%+62.40%+104.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Innoviva, Inc. stock logo
INVA
Innoviva
$20.77
-1.0%		$22.15
$16.52
▼
$25.15
$1.55B0.35759,119 shs799,097 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.80
-2.8%		$3.90
$2.23
▼
$6.51
$1.21B1.124.53 million shs5.26 million shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$3.02
+5.6%		$5.08
$2.74
▼
$8.59
$270.12M1.691.73 million shs7.82 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$31.13
-1.0%		$24.55
$13.50
▼
$44.60
$1.98B-1.03806,917 shs429,281 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Innoviva, Inc. stock logo
INVA
Innoviva
0.00%-2.19%-6.01%-9.26%+12.56%
MannKind Corporation stock logo
MNKD
MannKind
0.00%-5.33%-13.50%+37.68%+4.27%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.00%-49.02%-52.25%-40.42%-26.85%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
0.00%+3.46%+15.46%+62.40%+104.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Innoviva, Inc. stock logo
INVA
Innoviva
2.57
Moderate Buy$36.2074.29% Upside
MannKind Corporation stock logo
MNKD
MannKind
2.50
Moderate Buy$9.34145.89% Upside
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.00
Hold$5.3877.98% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
2.56
Moderate Buy$44.2942.26% Upside

Current Analyst Ratings Breakdown

Latest MYGN, ZBIO, INVA, and MNKD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/3/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$5.50 ➝ $3.00
7/31/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetHold$6.00 ➝ $4.00
7/30/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/30/2026
MannKind Corporation stock logo
MNKD
MannKind
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$11.00 ➝ $14.00
7/23/2026
MannKind Corporation stock logo
MNKD
MannKind
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/14/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/9/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/8/2026
MannKind Corporation stock logo
MNKD
MannKind
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
7/7/2026
MannKind Corporation stock logo
MNKD
MannKind
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/24/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy (B)
6/24/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Innoviva, Inc. stock logo
INVA
Innoviva
$411.33M3.73$4.98 per share4.17$15.71 per share1.32
MannKind Corporation stock logo
MNKD
MannKind
$348.97M3.36$0.06 per share63.19($0.17) per share-22.35
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$824.50M0.35$3.97 per share0.76$3.95 per share0.76
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$10M196.52N/AN/A$4.51 per share6.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Innoviva, Inc. stock logo
INVA
Innoviva
$271.17M$6.013.469.66N/A119.89%33.33%22.67%8/5/2026 (Estimated)
MannKind Corporation stock logo
MNKD
MannKind
$5.86M-$0.07N/A38.00N/A-6.63%-11.21%-3.92%8/5/2026 (Estimated)
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$365.90M-$1.19N/AN/AN/A-13.96%-16.09%-8.10%N/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$377.74M-$8.47N/AN/AN/AN/A-99.99%-58.06%8/11/2026 (Estimated)

Latest MYGN, ZBIO, INVA, and MNKD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.12N/AN/AN/A$15.00 millionN/A
8/5/2026Q2 2026
Innoviva, Inc. stock logo
INVA
Innoviva
$0.4360N/AN/AN/A$110.99 millionN/A
8/5/2026Q2 2026
MannKind Corporation stock logo
MNKD
MannKind
-$0.02N/AN/AN/A$108.80 millionN/A
7/30/2026Q2 2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.0579-$0.25-$0.1921-$0.46$206.03 million$190.70 million
5/13/2026Q1 2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.4742-$1.46+$0.0142-$1.46$25.00 millionN/A
5/6/2026Q1 2026
Innoviva, Inc. stock logo
INVA
Innoviva
$0.43$0.44+$0.01$2.22$101.57 million$97.99 million
5/6/2026Q1 2026
MannKind Corporation stock logo
MNKD
MannKind
-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 million
5/5/2026Q1 2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.06-$0.09-$0.03-$0.36$202.42 million$200.40 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Innoviva, Inc. stock logo
INVA
Innoviva
0.19
21.13
20.07
MannKind Corporation stock logo
MNKD
MannKind
N/A
1.87
1.50
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.40
2.21
1.98
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.04
11.94
11.94

Institutional Ownership

CompanyInstitutional Ownership
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
MannKind Corporation stock logo
MNKD
MannKind
49.55%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
99.02%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
Innoviva, Inc. stock logo
INVA
Innoviva
2.01%
MannKind Corporation stock logo
MNKD
MannKind
2.60%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
1.90%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
22.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
10073.81 million72.33 millionOptionable
MannKind Corporation stock logo
MNKD
MannKind
400308.95 million300.92 millionOptionable
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2,70094.45 million92.65 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A63.13 million49.24 millionN/A

Recent News About These Companies

Brokerages Set Zenas BioPharma, Inc. (NASDAQ:ZBIO) Target Price at $44.29
August 3 at 4:03 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30938738
Comparing Zenas BioPharma (NASDAQ:ZBIO) & Arcturus Therapeutics (NASDAQ:ARCT)
July 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30929655
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Moderate Buy" by Analysts
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharma-inc-nasdaqzbio-given-average-rating-of-moderate-buy-by-analysts-2026-07-29/
Exome Asset Management LLC Takes Position in Zenas BioPharma, Inc. $ZBIO
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-exome-asset-management-llc-takes-position-in-zenas-biopharma-inc-zbio-2026-07-28/
Zenas BioPharma (NASDAQ:ZBIO) Trading 7.7% Higher - Still a Buy?
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharma-nasdaqzbio-trading-77-higher-still-a-buy-2026-07-27/
125,232 Shares in Zenas BioPharma, Inc. $ZBIO Bought by Walleye Capital LLC
July 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-125232-shares-in-zenas-biopharma-inc-zbio-bought-by-walleye-capital-llc-2026-07-24/
SEB Asset Management AB Invests $3.20 Million in Zenas BioPharma, Inc. $ZBIO
July 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seb-asset-management-ab-invests-320-million-in-zenas-biopharma-inc-zbio-2026-07-24/
Jennison Associates LLC Buys Shares of 250,000 Zenas BioPharma, Inc. $ZBIO
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jennison-associates-llc-buys-shares-of-250000-zenas-biopharma-inc-zbio-2026-07-22/
Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees
July 17, 2026  |  quiverquant.comQ
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/17/3329284/0/en/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.2% - Time to Buy?
July 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharma-nasdaqzbio-stock-price-up-72-time-to-buy-2026-07-17/
Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise
July 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4921888-zenas-biopharma-obexelimab-could-build-an-autoimmune-franchise
Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential
July 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zenas-biopharma-zbio-best-ipo-135853785.html
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 8% - Here's Why
July 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharma-nasdaqzbio-trading-down-8-heres-why-2026-07-10/
Zenas BioPharma Inc ZBIO
June 27, 2026  |  morningstar.comM
Zenas BioPharma Announces Positive Phase 3 Obexelimab Results
June 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZBIO/pressreleases/36903055/zenas-biopharma-announces-positive-phase-3-obexelimab-results/
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
June 21, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/06/21/zenas-biopharma-s-ceo-purchased-60-000-company-shares-here-s-a-deeper-look-at-the-transaction/
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313812/0/en/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
June 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/11/3310795/0/en/zenas-biopharma-to-present-at-the-h-c-wainwright-7th-annual-neuro-perspectives-expert-summit.html
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR ...
June 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/zenas-biopharma-announces-data-registrational-230500180.html
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
June 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305741/0/en/zenas-biopharma-announces-data-from-the-registrational-phase-3-indigo-trial-of-obexelimab-in-immunoglobulin-g4-related-disease-igg4-rd-simultaneously-presented-at-the-eular-2026-co.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Innoviva stock logo

Innoviva NASDAQ:INVA

$20.77 -0.20 (-0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$20.88 +0.11 (+0.55%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

MannKind stock logo

MannKind NASDAQ:MNKD

$3.80 -0.11 (-2.81%)
Closing price 04:00 PM Eastern
Extended Trading
$3.88 +0.08 (+2.11%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Myriad Genetics stock logo

Myriad Genetics NASDAQ:MYGN

$3.02 +0.16 (+5.59%)
Closing price 04:00 PM Eastern
Extended Trading
$3.09 +0.07 (+2.28%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$31.13 -0.31 (-0.99%)
Closing price 04:00 PM Eastern
Extended Trading
$30.72 -0.41 (-1.32%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas